Relapsed/Refractory AML Clinical Trial
Official title:
CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.
| Status | Recruiting |
| Enrollment | 20 |
| Est. completion date | August 10, 2021 |
| Est. primary completion date | August 10, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A to 70 Years |
| Eligibility |
Inclusion Criteria: - Signed written informed consent - Aged < 70 years - Patients with relapsed/refractory AML - Cardiac: Left ventricular ejection fraction = 50% - Adequate renal and hepatic function - Performance status: Karnofsky = 70% Exclusion Criteria: - Pregnant or lactating females. - Any co-morbidity precluding the administration of CD123/CLL1 CAR-T Cells. |
| Country | Name | City | State |
|---|---|---|---|
| China | Fujian Medical University Union Hospital | Fuzhou | Fujian |
| Lead Sponsor | Collaborator |
|---|---|
| Fujian Medical University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Leukemia free survival | 1 year | ||
| Secondary | Adverse events that are related to treatment | 1 year |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04623944 -
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
|
Phase 1 | |
| Completed |
NCT01258816 -
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
|
Phase 1 | |
| Terminated |
NCT02520427 -
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
|
Phase 1 | |
| Recruiting |
NCT05054543 -
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
|
Phase 3 | |
| Not yet recruiting |
NCT05805072 -
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
|
N/A | |
| Completed |
NCT01319864 -
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
|
Phase 1 | |
| Recruiting |
NCT05428969 -
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04839341 -
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
|
Phase 1 |